Jump to content

Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Velaglucerase alfa: Difference between pages

(Difference between pages)
Page 1
Page 2
Content deleted Content added
VisualWikitext
Saving copy of the {{drugbox}} taken from revid 460520535 of page Velaglucerase_alfa for the Chem/Drugbox validation project (updated: 'UNII', 'ChEMBL').
 
no longer a stub
 
Line 1: Line 1:
{{Short description|Pharmaceutical drug}}
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid [{{fullurl:Velaglucerase_alfa|oldid=460520535}} 460520535] of page [[Velaglucerase_alfa]] with values updated to verified values.}}
{{Infobox drug
{{Drugbox
| Verifiedfields = changed
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 405295085
| verifiedrevid = 470629507
| IUPAC_name =
| image =
| image =
| width =
| alt =
| caption =


<!--Clinical data-->
<!-- Clinical data -->
| tradename =
| pronounce =
| tradename = Vpriv
| Drugs.com = {{drugs.com|monograph|velaglucerase-alfa}}
| MedlinePlus =
| DailyMedID = Velaglucerase alfa
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment =
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| pregnancy_category =
| routes_of_administration = [[Intravenous infusion|Intravenous]]
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| class =
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| ATC_prefix = A16
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| ATC_suffix = AB10
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| ATC_supplemental =
| legal_status = Rx

| routes_of_administration = Infusion
<!-- Legal status -->
| legal_AU = S4
| legal_AU_comment =
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment =
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment =
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment =
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment = <ref name="Vpriv FDA label" />
| legal_EU = Rx-only
| legal_EU_comment =
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment =
| legal_status = Rx-only


<!--Pharmacokinetic data-->
<!-- Pharmacokinetic data -->
| bioavailability = N/A
| bioavailability = N/A
| protein_bound =
| protein_bound =
| metabolism =
| metabolism =
| metabolites =
| onset =
| elimination_half-life = [[Blood plasma|Plasma]]: 5–12 minutes (absorbed by [[macrophage]]s)
| elimination_half-life = [[Blood plasma|Plasma]]: 5–12 minutes (absorbed by [[macrophage]]s)
| duration_of_action =
| excretion =
| excretion =


<!--Identifiers-->
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number =
| CAS_number = 884604-91-5
| CAS_supplemental =
| ATC_prefix = A16
| ATC_suffix = AB10
| PubChem =
| IUPHAR_ligand =
| ATC_supplemental =
| PubChem =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| DrugBank = DB06720
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = <!-- blanked - oldvalue: 23HYE36B0I -->
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = <!-- blanked - oldvalue: 1201865 -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = NA
| ChemSpiderID = none
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 23HYE36B0I
| KEGG_Ref =
| KEGG = D09029
| ChEBI_Ref =
| ChEBI =
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201865
| NIAID_ChemDB =
| PDB_ligand =
| synonyms =


<!--Chemical data-->
<!-- Chemical and physical data -->
| IUPAC_name =
| chemical_formula =
| C=2532 | H=3850 | N=672 | O=711 | S=16
| C=2532 | H=3850 | N=672 | O=711 | S=16
| SMILES =
| molecular_weight = 55.5 [[kDa]] (un[[glycosylate]]d)
| smiles =
| StdInChI =
| StdInChI_comment =
| StdInChIKey =
| density =
| density_notes =
| melting_point =
| melting_high =
| melting_notes =
| boiling_point =
| boiling_notes =
| solubility =
| sol_units =
| specific_rotation =
}}
}}

'''Velaglucerase alfa''', sold under the brand name '''Vpriv''', is a [[medication]] used for the treatment of [[Gaucher disease]] Type 1.<ref name="Vpriv FDA label" /> It is a hydrolytic [[lysosomal]] [[glucocerebroside]]-specific enzyme, which is a recombinant form of [[glucocerebrosidase]]. It has an identical amino acid sequence to the naturally occurring enzyme.<ref name="pmid21927713">{{cite journal | vauthors = Burrow TA, Grabowski GA | title = Velaglucerase alfa in the treatment of Gaucher disease type 1 | journal = Clinical Investigation | volume = 1 | issue = 2 | pages = 285–293 | date = February 2011 | pmid = 21927713 | pmc = 3172711 | doi = 10.4155/cli.10.21 }}</ref> It is manufactured by [[Shire plc]].

The most common side effects include abdominal (belly) pain, headache, dizziness, bone pain, arthralgia (joint pain), back pain, infusion-related reactions, asthenia (weakness) or fatigue (tiredness), and pyrexia (fever) or increased body temperature.<ref name="Vpriv EPAR" />

Velaglucerase alfa was approved for medical use in the United States in February 2010,<ref>{{cite web | work = Medical News Today | url = http://www.medicalnewstoday.com/articles/180630.php | title = Shire Announces FDA Approval Of Vpriv (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease | date = 27 February 2010 | access-date = 6 March 2010 | archive-date = 13 June 2011 | archive-url = https://web.archive.org/web/20110613222314/http://www.medicalnewstoday.com/releases/180630.php | url-status = dead }}</ref><ref>{{cite web | title=Drug Approval Package: Vpriv (Velaglucerase alfa) NDA #022575 | website=U.S. [[Food and Drug Administration]] (FDA) | date=24 February 2010 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022575s000TOC.cfm | access-date=17 February 2023 | archive-date=3 April 2021 | archive-url=https://web.archive.org/web/20210403003943/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022575s000TOC.cfm | url-status=live }}</ref> and in the European Union in August 2010.<ref name="Vpriv EPAR">{{cite web | title=Vpriv EPAR | website=[[European Medicines Agency]] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/vpriv | access-date=13 August 2020 | archive-date=29 October 2020 | archive-url=https://web.archive.org/web/20201029205412/https://www.ema.europa.eu/en/medicines/human/EPAR/vpriv | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref>

== Medical uses ==
Velaglucerase alfa is indicated for long-term enzyme-replacement therapy (ERT) in people with type-1 Gaucher disease.<ref name="Vpriv EPAR" /><ref name="Vpriv FDA label">{{cite web | title=Vpriv- velaglucerase alfa injection, powder, lyophilized, for solution | website=DailyMed | date=18 June 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf | access-date=13 August 2020 | archive-date=24 March 2021 | archive-url=https://web.archive.org/web/20210324151719/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf | url-status=live }}</ref>

==References==
{{reflist}}

{{Other alimentary tract and metabolism products}}
{{Portal bar | Medicine}}

[[Category:Recombinant proteins]]
[[Category:Orphan drugs]]
[[Category:Drugs developed by Takeda Pharmaceutical Company]]
Retrieved from "https://en.wikipedia.org/wiki/Special:ComparePages"